Avalyn Reports First Quarter 2026 Financial Results and Recent Business Highlights
Rhea-AI Summary
Avalyn (Nasdaq: AVLN) reported Q1 2026 results and pipeline progress. Cash, cash equivalents, and marketable securities were $123.1 million on March 31, 2026, excluding IPO proceeds. An upsized IPO raised $345.0 million, with total liquidity projected to fund operations into 2029.
MIST Phase 2b AP01 enrollment is on track to complete mid‑2026, AURA Phase 2 AP02 enrollment is underway with topline data expected in 2027, and AP03 Phase 1 is planned by end‑2026.
AI-generated analysis. Not financial advice.
Positive
- IPO gross proceeds of approximately $345.0 million at $18.00 per share
- Total cash and securities, including IPO net proceeds, expected to fund operations into 2029
- Q1 2026 R&D investment increased to $22.9 million from $15.3 million year over year
- MIST Phase 2b AP01 trial enrollment on track to complete by mid‑2026
- AURA Phase 2 AP02 trial dosing underway with topline data anticipated late 2027
- AP03 Phase 1 trial planned to start by the end of 2026
Negative
- Q1 2026 net loss widened to $26.9 million from $17.5 million year over year
- Q1 2026 G&A expenses rose to $5.0 million from $3.4 million year over year
News Market Reaction – AVLN
On the day this news was published, AVLN gained 2.64%, reflecting a moderate positive market reaction. Argus tracked a peak move of +11.2% during that session. Our momentum scanner triggered 4 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $29M to the company's valuation, bringing the market cap to $1.12B at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
No biotech peers were flagged in the momentum scanner, suggesting AVLN’s -3.53% move was driven by company-specific factors rather than a sector-wide rotation.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| May 27 | Conference participation | Neutral | +0.5% | Announcement of company overview presentation at Jefferies conference. |
| May 21 | Clinical data update | Positive | +1.4% | Upcoming EULAR 2026 poster with up to four-year AP01 tolerability data. |
| May 05 | Clinical conference posters | Positive | +1.0% | ATS 2026 posters on AP01 nebulizer usability and supportive care experiences. |
| May 03 | Third-party M&A mention | Neutral | -2.6% | Article highlighting investor track record that referenced Avalyn’s IPO. |
| May 01 | IPO closing | Neutral | -2.6% | Closing of Avalyn’s IPO and full exercise of underwriters’ option. |
Recent headlines around the IPO and conference appearances have produced modest, generally aligned price reactions, with no major divergences.
Over the last month, Avalyn transitioned to the public markets with an IPO on May 1, 2026 and has since focused on visibility and clinical positioning. News has highlighted conference participation, patient-centered AP01 delivery research, and upcoming EULAR 2026 AP01 data. IPO-related pieces on May 1–3 and subsequent conference updates in early May drew small but directionally consistent moves. Today’s Q1 2026 results and pipeline update build directly on that IPO narrative by detailing cash runway into 2029 and progress across AP01, AP02, and AP03.
Market Pulse Summary
This announcement details a classic post‑IPO setup: substantial new capital and an expanding late‑stage respiratory pipeline. Avalyn ended Q1 2026 with $123.1 million in cash and raised about $316.1 million net from its IPO, funding operations into 2029. Key programs include the 375‑patient MIST Phase 2b AP01 PPF trial and the 160‑patient AURA AP02 IPF study, along with planned AP03 Phase 1 work. Investors may watch upcoming EULAR data, enrollment progress, and the trajectory of R&D spend versus clinical milestones.
Key Terms
phase 2b medical
randomized medical
double blind medical
placebo-controlled medical
open-label extension medical
compassionate use medical
FVC medical
initial public offering (IPO) financial
AI-generated analysis. Not financial advice.
On track to complete enrollment of MIST Phase 2b trial of AP01 in progressive pulmonary fibrosis (PPF) in mid-2026, with newly presented long term open-label extension clinical data that support favorable tolerability profile
Enrollment underway in AURA Phase 2 trial of AP02 in patients with idiopathic pulmonary fibrosis (IPF) with topline data anticipated by the end of 2027
Upsized initial public offering (IPO) gross proceeds of
BOSTON, June 03, 2026 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc. (Nasdaq: AVLN), a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm of serious, rare respiratory diseases, today announced financial results for the first quarter ended March 31, 2026 and recent business highlights.
“Our recent IPO marks a transformative moment for Avalyn, providing the capital to advance three potentially paradigm-shifting programs in pulmonary fibrosis, a disease where current oral antifibrotics are limited by tolerability challenges that prevent many patients from receiving the full benefit of treatment," said Lyn Baranowski, CEO of Avalyn Pharma. "By delivering inhaled therapies directly to the lungs through nebulization, our programs are designed to address the urgent gap in treatments for these deadly diseases. The combination of anti-fibrotic activity seen in our clinical trials to date, together with the open-label extension data to be presented at EULAR in patients with PPF, reinforce our conviction that improved tolerability can unlock the potential for extended duration of treatment and clinical benefit. With clinical readouts across each of our three programs expected in 2027, we are executing with focus and discipline as we work to redefine the standard of care for patients living with this devastating disease."
Recent Pipeline Progress
AP01 (inhaled pirfenidone)
- MIST Phase 2b Trial On-Track to Complete Enrollment Mid-2026, with Multiple Recent Presentations Supporting its Clinical Profile.
- MIST is an ongoing Phase 2b randomized, double blind, placebo-controlled trial evaluating two doses of AP01 in patients with PPF. This 375-patient, 52-week trial is designed to assess safety and efficacy of AP01 with a primary endpoint of change in lung function measured by FVC. Enrollment is on-track to be completed mid-2026 with topline data anticipated in the second half of 2027.
- On June 6, 2026, the Company will present data from the PPF compassionate use cohort of its ATLAS open-label extension study at the European Alliance for Associations for Rheumatology (EULAR) Conference. Patients in this compassionate use cohort had late stage disease with no other treatment options. Study results indicate that after four years, AP01 remains generally well tolerated in these patients with PPF, with an adverse event profile consistent with that observed in the ATLAS Phase 1b trial. Though this study was not designed for efficacy, a favorable trend in lung function trajectory as measured by FVC was seen out to 48 months compared with published data. These AP01 data, combined with previously reported long-term extension data in patients with IPF, suggest the potential for AP01 to impact disease progression and survival in patients with pulmonary fibrosis.
- In May 2026, Avalyn presented two posters at the American Thoracic Society (ATS) Annual Meeting in Orlando, FL, demonstrating its commitment to patients, and both hearing and addressing their concerns. Posters summarized how patient, care partner, and physician input informed improvements in instruction materials for the eFlow® Nebulizer System for AP01, and described the importance of healthcare communication from the patient perspective.
AP02 (inhaled nintedanib)
- Enrollment Underway in AURA Phase 2 Trial. In March 2026, Avalyn announced first patient dosing in its AURA trial of AP02. AURA is a Phase 2 randomized, double-blind trial evaluating two doses of AP02 administered twice daily in patients with IPF. The 12-week study is designed to enroll 160 patients to assess safety and efficacy, as measured by FVC, with topline data anticipated in late 2027.
AP03 (inhaled combination of nintedanib and pirfenidone)
- Development Underway as Next-Generation Fixed-Dose Combination Therapy: A Phase 1 trial of AP03, a therapeutic approach combining nebulized pirfenidone and nintedanib, is on track to initiate by the end of 2026.
Recent Corporate Highlights
- In May 2026, the Company completed an upsized IPO, with the sale of 19,166,667 shares of its common stock, which included the full exercise by the underwriters of their option to purchase an additional 2,500,000 shares of common stock, at
$18.00 per share. The Company raised gross proceeds of approximately$345.0 million , before deducting underwriting discounts and commissions and other offering expenses. - Avalyn further strengthened its team to support the next phase of growth with the appointments of Adam Golden as General Counsel and Head of Business Development, and Frank Salisbury as Senior Vice President, Commercial.
Upcoming Conference
- Jefferies Global Healthcare Conference, New York City. Management will present a company overview on Thursday, June 4, 2026, at 9:55-10:25 a.m. ET. Access to the webcast can be found here.
Financial Results for First Quarter 2026
- Cash Position: Cash, cash equivalents, and marketable securities were
$123.1 million
as of March 31, 2026. This amount excludes the net proceeds of approximately
- Research & Development (R&D) Expenses: R&D expenses were
$22.9 million for the first quarter of 2026, as compared to$15.3 million for the first quarter of 2025. The increase in R&D expenses was primarily driven by the progression of the AP01 Phase 2b trial and on-going open label extension study, as well the AP02 Phase 2 trial. - General & Administrative (G&A) Expenses: G&A expenses were
$5.0 million for the first quarter of 2026, as compared to$3.4 million for the first quarter of 2025. The increase in G&A expenses was primarily driven by personnel-related expenses, including stock-based compensation. - Net loss: Net loss was
$26.9 million for the first quarter of 2026, as compared to$17.5 million for the first quarter of 2025.
About Avalyn Pharma
Avalyn aims to transform the treatment paradigm for pulmonary fibrosis and other serious, rare respiratory diseases. The company is advancing optimized inhaled formulations of established antifibrotic medicines designed to deliver drug directly to the lungs, enhance local efficacy, and reduce systemic side effects. Avalyn’s AP01 program is an optimized inhaled formulation of pirfenidone currently being evaluated in MIST, a global Phase 2b clinical trial in patients with progressive pulmonary fibrosis (PPF). AP01 has indicated encouraging safety and clinical activity across Phase 1b and multi-year open-label extension trials, with long-term data supporting the potential to preserve lung function while improving tolerability relative to historical oral pirfenidone. Avalyn’s AP02 program is an optimized inhaled formulation of nintedanib currently being evaluated in AURA, a global Phase 2 clinical trial in patients with idiopathic pulmonary fibrosis (IPF). Avalyn is also advancing AP03, an inhaled fixed-dose combination of pirfenidone and nintedanib, designed to deliver multiple antifibrotic mechanisms through a single lung-targeted platform. By leveraging its proprietary drug-device approach and deep expertise in rare respiratory disease development, Avalyn aims to establish a new standard of care in pulmonary fibrosis through inhaled, lung-targeted therapies. For more information, please visit avalynpharma.com and follow the company on LinkedIn.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements include, without limitation, implied and express statements about Avalyn’s beliefs and expectations regarding: the anticipated enrollment of the MIST Phase 2b trial of AP01 in PPF in mid-2026 and the interpretation and potential implications of clinical data; the ongoing enrollment in the AURA Phase 2 trial of AP02 in patients with IPF and the expected timing of results by the end of 2027; the potential of its product candidates to address significant unmet needs in the treatment of pulmonary fibrosis and related diseases; the possibility that improved tolerability may translate into clinically meaningful benefit; the advancement of its pulmonary fibrosis programs; the planned initiation of a Phase 1 trial of AP03 by the end of 2026; and the potential for any of the Company’s product candidates to establish or contribute to a new standard of care; and Avalyn’s expectations regarding the anticipated timeline of its cash runway and future financial performance.
Any forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, risks associated with: the risk that earlier results may not be indicative of future results, risks related to clinical trial site activation, delays in enrollment generally or enrollment rates that are lower than expected; delays related to assessment of clinical trial results; risks related to unexpected safety or efficacy data observed during clinical studies; risks related to volatile market and economic conditions, risks related to our ability to protect and maintain our intellectual property position or relationships with third-parties, the initiation, timing, progress and results of our current and future research and development programs, preclinical studies and clinical trials; our ability to successfully complete our clinical trials; our ability to advance any product candidates that we may identify and successfully complete any clinical studies, including the manufacture of any such product candidates; the likelihood of our clinical trials demonstrating safety and efficacy of our product candidates; and risks related to needs for additional financing. These and other risks and uncertainties are described in greater detail in the section entitled “Risk Factors” in Avalyn’s current and future filings with the Securities and Exchange Commission, including those described from time to time under the caption “Risk Factors.” In addition, any forward-looking statements represent Avalyn’s views only as of today and should not be relied upon as representing its views as of any subsequent date. Avalyn explicitly disclaims any obligation to update any forward-looking statements subject to any obligations under applicable law. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.
Investor Contact:
Cassie Saitow, Avalyn Pharma Inc.
Sr. Director, IR and Corporate Communications
ir@avalynpharma.com
Media Contact:
Kat Lippincott, Deerfield Group
kat.lippincott@deerfieldgroup.com
media@avalynpharma.com
Financial Tables
| AVALYN PHARMA INC. | |||||||
| CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS | |||||||
| (In thousands, except share and per share amounts) | |||||||
| (Unaudited) | |||||||
| Three Months Ended March 31, | |||||||
| 2026 | 2025 | ||||||
| OPERATING EXPENSES: | |||||||
| Research and development | $ | 22,889 | $ | 15319 | |||
| General and administrative | 5,020 | 3397 | |||||
| Total operating expenses | 27,909 | 18716 | |||||
| LOSS FROM OPERATIONS | (27,909 | ) | (18,716 | ) | |||
| OTHER INCOME (EXPENSE): | |||||||
| Interest income | 1,125 | 1248 | |||||
| Interest expense | (98 | ) | — | ||||
| Other expense | 13 | (35 | ) | ||||
| Total other income | 1,040 | 1213 | |||||
| NET LOSS | $ | (26,869 | ) | $ | (17503 | ) | |
| AVALYN PHARMA INC. | |||||||
| CONSOLIDATED BALANCE SHEET DATA | |||||||
| (In thousands) | |||||||
| (Unaudited) | |||||||
| March 31, | December 31, | ||||||
| 2026 | 2025 | ||||||
| Cash, cash equivalents, and marketable securities | $ | 123,127 | $ | 138359 | |||
| Total assets | 135,663 | 148881 | |||||
| Total liabilities | 27,687 | 15316 | |||||
| Total stockholders’ deficit and redeemable convertible preferred stock | $ | 107,976 | $ | 133565 | |||
